LRRK2 and Parkinson disease: Similar results were obtained using the fibroblasts of a LRRK2 G2019S Parkinson’s patient, in which lysosomal morphology defects were corrected with molecular TPC2-silencing or pharmacological inhibition of TPCs [40].